CTA-PA — EIDP, Inc.

Summary of Corteva Agriscience Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Performance: Organic sales decreased by 4% year-over-year, with Crop Protection volumes down 2% and prices down 1%. Seed prices increased by 3%, but volumes fell 8%.
• Full Year Results: Organic sales increased by 4%, with operating EBITDA rising 14% to $3.85 billion, achieving an operating EBITDA margin of over 22%, a 215 basis point improvement.
• Free Cash Flow: Improved significantly to $2.9 billion, up $1.2 billion from the previous year, driven by higher EBITDA and working capital discipline.
• SG&A and R&D: SG&A expenses rose to $860 million from $735 million, largely due to increased compensation expenses. R&D expenses increased by $50 million.

2. Strategic Updates and Business Highlights

• Separation Update: Corteva is on track for a separation in the second half of 2026, with a new CEO expected to be announced soon. The company anticipates launching a new brand identity for SpinCo.
• Bayer Agreement: A comprehensive resolution with Bayer allows Corteva to accelerate its corn licensing business and enter the cotton market, projecting approximately $1 billion in additional earnings over the next decade.
• Seed Business Growth: The Seed business achieved organic growth across all regions, with significant cost improvements and share gains in corn and soybeans.
• Crop Protection Pipeline: A robust $9 billion pipeline of differentiated technologies is in place, with expectations for modest growth in 2026.

3. Forward Guidance and Outlook

• 2026 Guidance: Corteva expects operating EBITDA to be between $4 billion and $4.2 billion, representing a 7% increase at the midpoint. Operating EPS is projected to be between $3.45 and $3.70 per share.
• Market Conditions: Anticipated modest growth in the Crop Protection market, with pricing pressures expected to continue in certain regions, particularly Latin America.
• Royalty Neutrality: The company expects to achieve royalty neutrality in 2026, two years ahead of previous estimates.

4. Challenges and Points of Concern

• Volume Declines: Notable declines in volumes for both Seed and Crop Protection in Q4 due to seasonal shifts and competitive pricing pressures, particularly in Latin America.
• Pricing Pressures: Competitive pricing dynamics in major markets, especially in Crop Protection, are expected to persist, impacting margins.
• Currency Headwinds: Currency fluctuations, particularly in Brazil, Canada, and Turkey, have negatively affected EBITDA, with a $217 million headwind noted for the year.

5. Notable Q&A Insights

• Bayer Agreement Details: The agreement enhances Corteva's licensing capabilities and resolves ongoing litigation, providing freedom to operate and access to new markets.
• Gene Editing Developments: Positive regulatory developments in Europe regarding gene editing could open new markets for Corteva's products, with expectations for commercialization of multi-disease resistant corn in the U.S. within one to two years.
• Farmer Sentiment: Farmers in Latin America are experiencing tight cash flow due to high interest rates and commodity price pressures, but overall demand for differentiated products remains strong.
• Order Book Strength: Corteva's order books for both Seed and Crop Protection are strong, with prepay collections on par with prior years, indicating a solid start to 2026.

This summary encapsulates the key financial results, strategic updates, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Corteva Agriscience's performance and outlook.